Log in

NASDAQ:BPTH - Bio-Path Stock Price, Forecast & News

-0.28 (-3.96 %)
(As of 01/24/2020 04:00 PM ET)
Today's Range
Now: $6.79
50-Day Range
MA: $7.69
52-Week Range
Now: $6.79
Volume146,033 shs
Average Volume140,134 shs
Market Capitalization$19.58 million
P/E RatioN/A
Dividend YieldN/A
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BPTH



Sales & Book Value

Annual Sales$40,000.00
Book Value$1.79 per share


Net Income$-8,580,000.00


Market Cap$19.58 million
Next Earnings Date3/18/2020 (Estimated)
OptionableNot Optionable

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) announced its earnings results on Friday, November, 15th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.04. View Bio-Path's Earnings History.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release their next quarterly earnings announcement on Wednesday, March 18th 2020. View Earnings Estimates for Bio-Path.

What price target have analysts set for BPTH?

1 brokers have issued twelve-month target prices for Bio-Path's shares. Their forecasts range from $25.00 to $25.00. On average, they expect Bio-Path's share price to reach $25.00 in the next year. This suggests a possible upside of 268.2% from the stock's current price. View Analyst Price Targets for Bio-Path.

What is the consensus analysts' recommendation for Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Path.

What are Wall Street analysts saying about Bio-Path stock?

Here are some recent quotes from research analysts about Bio-Path stock:
  • 1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (12/4/2019)
  • 2. HC Wainwright analysts commented, "We believe quarterly operating expenses could approximate $2M in 2H19. The company had $17.1M in cash at the end of June 2019, which should support operations into 2H20. In the wake of this update, we reiterate our Buy rating and $28 price target. Combo trial of prexigebersen + decitabine could report safety data in 2H19. Prexigebersen is an antisense DNA molecule that blocks expression of growth factor receptor-bound protein 2 (Grb-2). Prexigebersen has shown favorable safety and positive Phase 2 interim data in combination with low-dose cytarabine (LDAC) in elderly patients with acute myeloid leukemia (AML), demonstrating 65% objective response with a 29% complete response (CR) rate." (8/16/2019)

Has Bio-Path been receiving favorable news coverage?

News coverage about BPTH stock has been trending somewhat positive on Saturday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bio-Path earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Bio-Path.

Are investors shorting Bio-Path?

Bio-Path saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 133,300 shares, a decrease of 7.9% from the November 28th total of 144,800 shares. Based on an average trading volume of 131,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 5.0% of the company's stock are short sold. View Bio-Path's Current Options Chain.

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $6.79.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $19.58 million and generates $40,000.00 in revenue each year. The company earns $-8,580,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Bio-Path employs 8 workers across the globe.View Additional Information About Bio-Path.

What is Bio-Path's official website?

The official website for Bio-Path is http://www.biopathholdings.com/.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]

MarketBeat Community Rating for Bio-Path (NASDAQ BPTH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel